The Biosimilar Red Tape Elimination Act would deem all biosimilars interchangeable with their reference products without the U.S. Food and Drug Administration (FDA) needing to make any additional determination. The bill would do away with important scientific standards while failing to address the broader misaligned incentives in the marketplace allowing pharmacy benefit managers (PBMs) to block biosimilar competition and profit off medicines at the expense of patients.